1 week Ago By Defense World Staff
Orion Portfolio Solutions LLC reduced its stake in Inari Medical, Inc. ( NASDAQ:NARI – Free Report ) by 9.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission.
The fund owned 14,157 shares of the company’s stock after selling 1,403 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Inari Medical were worth $723,000 as of its most recent SEC filing. Several other large investors have also bought and sold shares of the stock.
Pictet Asset Management Holding SA raised its holdings in shares of Inari Medical by 12.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 7,935 shares of the company’s stock valued at $405,000 after purchasing an additional 909 shares during the last quarter.
Norges Bank bought a new position in shares of Inari Medical during the 4th quarter worth approximately $14,447,000. EntryPoint Capital LLC purchased a new position in shares of Inari Medical in the 4th quarter worth approximately $388,000. Prudential Financial Inc.
grew its holdings in shares of Inari Medical by 9.2% in the fourth quarter. Prudential Financial Inc.
now owns 170,400 shares of the company’s stock valued at $8,699,000 after acquiring an additional 14,290 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Inari Medical by 0.
5% during the fourth quarter. Vanguard Group Inc. now owns 5,628,875 shares of the company’s stock valued at $287,354,000 after acquiring an additional 30,702 shares during the last quarter.
90.98% of the stock is currently owned by institutional investors. Analyst Ratings Changes A number of research firms have weighed in on NARI.
Piper Sandler boosted their target price on shares of Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a research note on Tuesday, January 7th.
Robert W. Baird reissued a “neutral” rating and set a $80.00 price objective (down from $81.
00) on shares of Inari Medical in a report on Tuesday, January 7th. Wells Fargo & Company restated an “equal weight” rating and issued a $80.00 target price (up from $65.
00) on shares of Inari Medical in a research note on Tuesday, January 7th. Truist Financial lifted their price objective on Inari Medical from $50.00 to $63.
00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Finally, Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 price objective (up from $74.
00) on shares of Inari Medical in a report on Tuesday, January 7th. Twelve equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Inari Medical currently has a consensus rating of “Hold” and an average target price of $68.
00. Inari Medical Stock Performance NARI opened at $79.97 on Monday.
The stock has a market capitalization of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.
02. The stock has a 50-day moving average price of $79.91 and a 200-day moving average price of $62.
77. Inari Medical, Inc. has a 12-month low of $36.
73 and a 12-month high of $79.99. About Inari Medical ( Free Report ) Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States.
The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. Featured Articles Five stocks we like better than Inari Medical How Technical Indicators Can Help You Find Oversold Stocks Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential? What Investors Need to Know About Upcoming IPOs Disney 2025 Shareholders: Major Updates for Investors How to invest in marijuana stocks in 7 steps Advance Auto Parts Stock: A Classic Rebound Play in the Making Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter .
.
